Navigation Links
Depomed Announces Appointment of Vicente J. Anido, Jr., Ph.D. to Board of Directors, and Retirement of Directors Julian N. Stern and Craig R. Smith, M.D.
Date:2/11/2013

NEWARK, Calif., Feb. 11, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) today announced the appointment of Vicente Anido, Jr. , Ph.D., 60, to the company's Board of Directors.  Dr. Anido is the former President and Chief Executive Officer of ISTA Pharmaceuticals, which was acquired by Bausch + Lomb Incorporated in June 2012. 

"We are thrilled to have Vince join our Board of Directors," said James Schoeneck , Depomed's President and CEO. "Vince's significant depth and breadth of experience in the specialty pharmaceutical industry will be invaluable to Depomed as we drive the commercial success of our products and create new opportunities for growth," Mr. Schoeneck added.

"I am excited to join Depomed's Board of Directors," said Dr. Anido. "The company's product portfolio, commercial organization and experienced management team are great assets, and I look forward to contributing to Depomed's growth and success."

Prior to joining ISTA Pharmaceuticals as President and CEO in 2000, Dr. Anido served as a general partner of Windamere Venture Partners.  From 1996 to 1999, Dr. Anido served as President and Chief Executive Officer of CombiChem, Inc., a drug discovery company.  From 1993 to 1996, Dr. Anido served as President of the Americas Region of Allergan, Inc., where he was responsible for Allergan's commercial operations for North and South America.  Prior to Allergan, Dr. Anido spent 17 years in management positions at Marion Laboratories and Marion Merrell Dow , Inc., including as Vice President, Business Management of Marion's U.S. Prescription Products Division.  Dr. Anido received a B.S. and a M.S. from West Virginia University and a Ph.D. from the University of Missouri, Kansas City.

Depomed also announced today the retirement of Julian N. Stern and Craig R. Smith , M.D. as directors of Depomed, effective upon the election of directors at the Company's 2013 Annual Meeting of Shareholders. 

"I would like to thank Julian and Craig for their years of service and commitment to Depomed and its shareholders," said Peter Staple , the Chairman of Depomed's Board of Directors. "They have been important contributors to Depomed's development and growth, and I know I speak for everyone at Depomed in expressing our great appreciation for their service and the opportunity to work with them," Mr. Staple added.

About Depomed

Depomed, Inc. is a specialty pharmaceutical company with three approved and marketed products. Gralise® (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia (PHN). Zipsor® (diclofenac potassium) Liquid Filled Capsules is a non-steroidal anti-inflammatory drug (NSAID) indicated for relief of mild to moderate acute pain in adults. Glumetza® (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and is commercialized by Santarus, Inc. in the United States. Depomed formulates its products and product candidates with its proven, proprietary Acuform® drug delivery technology, which is designed to improve existing oral medications, allowing for extended release of medications to the upper gastrointestinal tract when dosed with food. Additional information about Depomed may be found on its website, www.depomed.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995. The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties including, but not limited to, those related to the company's anticipated future growth, and other risks detailed in the company's Securities and Exchange Commission filings, including the company's Annual Report on Form 10-K for the year ended December 31, 2011 and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2012. The inclusion of forward-looking statements should not be regarded as a representation that any of the company's plans or objectives will be achieved. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

CONTACT:
August J. Moretti
Depomed, Inc.
510.744.8000
amoretti@depomed.com


'/>"/>
SOURCE Depomed, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Depomed To Present At Oppenheimer 2012 Healthcare Conference
2. Depomed Reports Top Line Data for Phase 2 Study in Parkinsons Disease
3. Depomed To Present At Lazard 2012 Healthcare Conference
4. Depomed Reports Third Quarter Financial Results
5. Depomed To Report Third Quarter Fiscal Year 2012 Financial Results On Monday, November 5, 2012
6. Depomed To Present At UBS Global Life Sciences Conference
7. Depomed To Present At Morgan Stanley 2012 Healthcare Conference
8. Depomed To Present At Stifel Nicolaus 2012 Healthcare Conference
9. Depomed To Report Second Quarter Fiscal Year 2012 Financial Results On Thursday, August 2, 2012
10. Depomed To Present At JMP Securities 7th Annual Healthcare Conference
11. Depomed Announces Filing Of Shelf Registration To Replace Existing Shelf
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)...  MedSource announced today that it has selected ... of choice.  This latest decision demonstrates MedSource,s commitment ... clients by offering a state-of-the-art electronic data capture ... as the EDC platform of choice in exchange ... has long been a preferred EDC platform by ...
(Date:6/23/2016)... 2016  In a startling report released today, National Safety ... lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... how states are tackling the worst drug crisis in recorded U.S. ... Kentucky , New Mexico , ... Of the 28 failing states, three – Michigan ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... ... have been diagnosed with endometriosis. These women need a treatment plan to not ... comprehensive approach that can help for preservation of fertility and ultimately achieving a ...
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
Breaking Medicine News(10 mins):